Paving Way for Pediatric Drug Safety - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Paving Way for Pediatric Drug Safety

Pharmaceutical Technology

Angie Drakulich
Did you know that only one-third of prescribed pediatric drugs have been studied or labeled for pediatric use? The Best Pharmaceuticals for Children Act (BPCA) was enacted in 2002 to improve this statistic by providing companies with six months of additional marketing exclusivity if they conduct pediatric trials. The Government Accountability Office recently issued a report that examined data from studies conducted between 2002 and 2005 for drugs specified by the US Food and Drug Administration under BPCA.

According to the report, companies agreed to approximately 80% of FDA written requests to conduct pediatric studies under BPCA. The act also helped usher in labeling changes for nearly 90% of the drugs granted pediatric exclusivity. Although approving these labeling changes took three years in some cases, BPCA has had a positive effect on overall pediatric drug safety in terms of increasing information, trials, and accurate labeling. In fact, in 2006, Trileptal became the 100th FDA-approved drug to include appropriate labeling information about safety, efficacy, dosing, and unique risks for children and teens.

But we shouldn't stop there. At press time, Congress was debating BPCA's reauthorization, along with that of the Pediatric Research Equity Act of 2003 (PREA)—which enables FDA to require pediatric studies whenever a new ingredient, indication, dosage form, dosage regimen or route of administration is proposed for approval. Both acts fall under the pending renewal of the Prescription Drug User Fee Act. Some legislators would like to scale back BPCA's exclusivity period, claiming that companies earn far more during those six months of exlusivity than it costs to carry out a pediatric trial and that exclusivity can block potential generic drugs from entering the market.

Although these points may be warranted, Congress should consider the larger picture. Renewing BPCA and PREA will keep us on the path toward helping drug manufacturers produce safe and reliable medications for children.

Angie Drakulich is the managing editor of Pharmaceutical Technology,


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here